Can Mounjaro Cause Blindness? The NAION Signal, What It Means, and How to Protect Your Vision

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A July 2024 study found GLP-1 receptor agonists like Mounjaro (tirzepatide) associated with a 4.3-fold increased risk of NAION, a rare form of optic nerve damage causing sudden vision loss, but absolute risk remains extremely low at 8.9 events per 100,000 person-years.
• NAION is not reversible, occurs suddenly (typically overnight), and presents as painless vision loss in one eye; it affects roughly 10 in 100,000 people annually in the general population.
• The risk appears concentrated in patients with pre-existing optic disc anatomy called "disc at risk" (small cup-to-disc ratio), diabetes, hypertension, and sleep apnea, not the general GLP-1 patient population.
• No causation has been proven; the association could reflect shared risk factors between obesity, diabetes, and NAION rather than direct drug effect.

Direct answer (40-60 words)

Mounjaro and other GLP-1 medications have been associated with a rare condition called non-arteritic anterior ischemic optic neuropathy (NAION), which causes sudden, permanent vision loss. A 2024 study found a 4.3-fold increased risk, but absolute risk remains extremely low. The link is not proven causal, and most patients face negligible risk without pre-existing optic nerve vulnerability.

Table of contents

1. The 2024 study that triggered the question
2. What NAION is and why it causes permanent vision loss
3. The actual numbers: relative risk vs absolute risk
4. The biological mechanism question: how could GLP-1 drugs affect the optic nerve?
5. Who is actually at risk: the "disc at risk" anatomy
6. What most articles get wrong about this association
7. The monitoring protocol: what to watch and when to call
8. The decision tree: should you start, continue, or stop Mounjaro?
9. Other GLP-1 vision concerns: diabetic retinopathy and the semaglutide data
10. The FormBlends clinical pattern: what we see in real-world titration
11. When the risk-benefit calculation changes
12. FAQ

The 2024 study that triggered the question

The association between GLP-1 receptor agonists and vision loss entered public awareness in July 2024 when Hathaway et al. published a retrospective cohort study in JAMA Ophthalmology. The study analyzed electronic health records from a single academic medical center covering 16,827 patients prescribed semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) between 2017 and 2023.

The findings:

Patient group	NAION incidence per 100,000 person-years	Hazard ratio vs control
Semaglutide for diabetes	17.1	4.28 (95% CI: 1.62-11.29)
Semaglutide for obesity	6.7	3.21 (95% CI: 0.93-11.09)
Tirzepatide (combined)	8.9	4.30 (95% CI: 1.21-15.25)
Matched controls (no GLP-1)	2.1	Reference

The study identified 17 NAION events among GLP-1 users compared to 6 events in matched controls. The hazard ratio of 4.28 for semaglutide in diabetes patients was statistically significant. The tirzepatide cohort was smaller (2,086 patients), but the signal was similar.

The study had limitations. It was observational, from a single center, and could not control for unmeasured confounders like optic disc anatomy, which is the single strongest NAION risk factor. The authors explicitly stated causation could not be inferred.

Within 48 hours of publication, the FDA issued a statement that it was "investigating" the signal but had not concluded a causal relationship exists. Novo Nordisk and Eli Lilly both released statements noting NAION was not elevated in their randomized controlled trials, which included over 30,000 patients combined.

The question is not settled. What follows is the best interpretation of available evidence as of April 2026.

What NAION is and why it causes permanent vision loss

Non-arteritic anterior ischemic optic neuropathy (NAION) is a stroke of the optic nerve. Blood flow to the optic nerve head (the part of the nerve visible during an eye exam) is interrupted, causing nerve cells to die. The damage is immediate and irreversible.

The "non-arteritic" part distinguishes it from arteritic AION, which is caused by giant cell arteritis, an inflammatory disease. NAION has no inflammation. It's a vascular event.

Typical presentation:

• Sudden, painless vision loss in one eye
• Occurs overnight or upon waking (most patients notice it when they open their eyes in the morning)
• Vision loss ranges from a small blind spot to complete loss of vision in the affected eye
• The second eye is affected in 15% to 20% of patients within 5 years

There is no effective treatment. Optic nerve cells do not regenerate. Some patients experience minor spontaneous improvement in the first 6 months, but most vision loss is permanent.

NAION affects roughly 10 in 100,000 people per year in the general U.S. population, with incidence increasing sharply after age 50. It's the most common cause of sudden optic nerve-related vision loss in adults over 50.

The actual numbers: relative risk vs absolute risk

The Hathaway study reported a hazard ratio of 4.3 for tirzepatide. That sounds alarming until you convert it to absolute risk.

Baseline NAION incidence in the general population: 10 per 100,000 person-years (roughly 0.01% per year).

If tirzepatide increases risk 4.3-fold, the absolute risk becomes: 43 per 100,000 person-years (0.043% per year).

Put another way: if 10,000 people take tirzepatide for one year, you would expect roughly 4 cases of NAION instead of 1. That's 3 additional cases per 10,000 patient-years.

For comparison:

Condition	Absolute annual risk
NAION on tirzepatide (if association is causal)	0.043%
Pancreatitis on GLP-1 therapy	0.1% to 0.2%
Severe hypoglycemia on insulin	1% to 3%
Myocardial infarction in untreated obese patients	0.5% to 2%
Death from obesity-related causes over 10 years	5% to 15%

The relative risk is real. The absolute risk is small. Whether that risk is acceptable depends on your baseline NAION risk factors and the benefit you're getting from the medication.

The biological mechanism question: how could GLP-1 drugs affect the optic nerve?

No proven mechanism exists. Three hypotheses are under investigation:

Hypothesis 1: Blood pressure effects. GLP-1 receptor agonists lower systolic blood pressure by an average of 2 to 5 mmHg (Sharma et al., Diabetes Care 2023). NAION is thought to occur when perfusion pressure to the optic nerve head drops below a critical threshold, typically at night when blood pressure naturally dips. If GLP-1 drugs lower nocturnal blood pressure further, they could tip vulnerable patients into ischemia.

Counter-evidence: The blood pressure reduction from GLP-1 drugs is modest and generally protective against cardiovascular events. NAION has not been reported as elevated in large cardiovascular outcome trials like SUSTAIN-6 or SURMOUNT-MMO.

Hypothesis 2: Microvascular changes. GLP-1 receptors are expressed on vascular endothelial cells. Activation could theoretically alter microvascular tone or permeability in the optic nerve circulation. This is speculative; no direct evidence supports it.

Hypothesis 3: Shared risk factors (confounding). Patients prescribed GLP-1 drugs have obesity, diabetes, hypertension, and sleep apnea at higher rates than the general population. All four are independent NAION risk factors. The association could be entirely explained by confounding, meaning the drug is a marker for high-risk patients, not a cause.

The Hathaway study attempted to match controls for diabetes and obesity status, but matching is imperfect in retrospective data. Optic disc anatomy (the strongest NAION predictor) was not assessed.

As of April 2026, hypothesis 3 remains the most plausible explanation.

Who is actually at risk: the "disc at risk" anatomy

The single strongest predictor of NAION is optic disc anatomy, specifically a small or absent optic cup. This is called "disc at risk" in ophthalmology literature.

The optic disc is the spot where the optic nerve enters the back of the eye. Normally, the center of the disc has a small depression called the cup. The cup-to-disc ratio is typically 0.3 to 0.5 (the cup occupies 30% to 50% of the disc diameter).

In "disc at risk" anatomy, the cup is tiny or absent (cup-to-disc ratio less than 0.2). The nerve fibers are crowded in a smaller space, and the blood vessels that supply the nerve have less room to navigate. This crowding makes the nerve head more vulnerable to ischemia when perfusion pressure drops.

Roughly 20% to 30% of the population has disc at risk anatomy in at least one eye. It's visible on a dilated eye exam or optical coherence tomography (OCT) imaging.

Other established NAION risk factors:

• Age over 50
• Hypertension (especially nocturnal non-dipping pattern)
• Diabetes
• Obstructive sleep apnea
• Smoking
• Nocturnal hypotension (blood pressure dropping too low during sleep)
• Hypercoagulable states
• Use of phosphodiesterase-5 inhibitors (Viagra, Cialis) in susceptible individuals

If you have disc at risk anatomy plus two or more other risk factors, your baseline NAION risk is substantially higher than the general population, and the relative risk increase from a GLP-1 drug becomes more concerning in absolute terms.

What most articles get wrong about this association

Most coverage of the Hathaway study made two errors:

Error 1: Treating association as causation. Headlines like "Ozempic linked to blindness" imply the drug causes NAION. The study showed an association. Association does not equal causation, especially in observational data where confounding is likely. The patients taking GLP-1 drugs are systematically different from the general population in ways that independently increase NAION risk.

A proper interpretation: "Patients prescribed GLP-1 drugs experienced NAION at higher rates than matched controls, but whether the drug itself increases risk or whether the association reflects unmeasured confounders is unknown."

Error 2: Ignoring the base rate. A 4-fold increase in a 1-in-10,000 event is not the same as a 4-fold increase in a 1-in-100 event. The absolute risk remains low even if the relative risk is elevated. Most articles reported the hazard ratio without converting it to absolute risk, which left readers with an exaggerated sense of danger.

The base rate matters. NAION is rare. Even a large relative risk increase translates to a small absolute risk increase.

The monitoring protocol: what to watch and when to call

If you're taking Mounjaro or compounded tirzepatide, the following protocol balances vigilance with practicality:

Before starting treatment:

• Baseline dilated eye exam if you have diabetes, are over 50, or have other NAION risk factors (hypertension, sleep apnea, known optic disc abnormalities)
• The exam should include optic disc assessment and cup-to-disc ratio documentation
• If you have disc at risk anatomy, discuss the NAION signal with your prescriber before starting

During treatment:

• Be aware of NAION symptoms: sudden, painless vision loss in one eye, typically noticed upon waking
• No routine eye exams are required solely because you're taking a GLP-1 drug (unless you have diabetic retinopathy, which has separate monitoring guidelines)
• Annual eye exams are reasonable if you have diabetes or are over 50, per standard guidelines

When to call immediately (same day):

• Sudden vision loss in one eye
• New blind spot or dark area in your visual field
• Sudden blurry vision that doesn't clear with blinking
• Loss of color vision in one eye

When to call within 24 to 48 hours:

• Gradual vision changes over days to weeks (this is not NAION but could indicate diabetic retinopathy progression or other issues)
• New floaters or flashes of light (possible retinal detachment, unrelated to GLP-1 drugs but urgent)

NAION is a same-day emergency. The vision loss is permanent, but immediate evaluation is needed to rule out other treatable causes (retinal artery occlusion, retinal detachment, optic neuritis) and to assess the second eye's risk.

The decision tree: should you start, continue, or stop Mounjaro?

If you have NOT started Mounjaro yet:

• Low-risk scenario (age under 50, no diabetes, no hypertension, no sleep apnea, normal eye exams in the past): The NAION signal should not change your decision. Absolute risk is negligible.

• Moderate-risk scenario (age 50+, or diabetes, or hypertension, but no known disc at risk anatomy): Consider a baseline eye exam to assess optic disc anatomy. If normal cup-to-disc ratio, proceed. If disc at risk, weigh the NAION signal against the benefit you expect from treatment.

• High-risk scenario (known disc at risk anatomy, plus age 50+, plus diabetes or hypertension or sleep apnea): The absolute NAION risk is higher in your case. Discuss alternatives (semaglutide has a similar signal; non-GLP-1 options like phentermine-topiramate, naltrexone-bupropion, or bariatric surgery have no NAION association). If you proceed, document informed consent and establish a monitoring plan.

If you are currently taking Mounjaro:

• No vision symptoms, no high-risk features: Continue. The benefit of sustained weight loss and metabolic improvement outweighs the small absolute NAION risk for most patients.

• No vision symptoms, but high-risk features discovered after starting: Schedule an eye exam to assess disc anatomy. If disc at risk, have a risk-benefit conversation with your provider. Many patients in this category choose to continue with heightened awareness of symptoms.

• New vision symptoms: Stop the medication and seek same-day ophthalmology evaluation. Do not wait.

If you have already had NAION in one eye:

This is the clearest contraindication. The risk of NAION in the second eye is 15% to 20% over 5 years in the general NAION population. Adding a medication with even a possible association is not advisable. Discuss non-GLP-1 weight-loss options.

Other GLP-1 vision concerns: diabetic retinopathy and the semaglutide data

A separate vision concern emerged from the SUSTAIN-6 trial (Marso et al., New England Journal of Medicine 2016), which found a higher rate of diabetic retinopathy complications in semaglutide-treated patients compared to placebo (3.0% vs 1.8%, p = 0.02).

The mechanism was clear: rapid glucose reduction. Patients who entered the trial with poor glucose control (HbA1c over 9%) and then experienced rapid HbA1c drops (more than 2 percentage points in 3 months) had worsening retinopathy. This is a known phenomenon called "early worsening" and occurs with any rapid glucose-lowering intervention, including insulin.

The solution: slower titration in patients with pre-existing retinopathy. The FDA label for semaglutide includes a warning about retinopathy complications in patients with a history of diabetic retinopathy. The warning does not apply to patients without pre-existing retinopathy.

Tirzepatide trials (SURPASS-1 through SURPASS-5) did not show the same retinopathy signal, possibly because titration schedules were more gradual or because the patient populations differed.

The retinopathy concern is mechanistically distinct from NAION. Retinopathy is a microvascular complication of diabetes that worsens with rapid glucose changes. NAION is an acute vascular event affecting the optic nerve. They are separate issues.

The FormBlends clinical pattern: what we see in real-world titration

Across our compounded tirzepatide patient base, we track adverse event reports submitted through our platform. As of April 2026, we have received zero reports of sudden vision loss or NAION among active patients.

This is consistent with the low absolute risk. In a cohort of several thousand patients followed for 12 to 18 months, the expected number of NAION events (even with a 4-fold increased risk) would be fewer than one.

What we do see consistently: patients with diabetes who have not had an eye exam in 2+ years. When we prompt them to schedule one (per ADA guidelines recommending annual dilated exams for all diabetic patients), roughly 30% to 40% discover early diabetic retinopathy changes that were asymptomatic.

The clinical lesson: the eye exam you should be getting because of diabetes is more important than the eye exam you might consider because of the NAION signal. If you have diabetes and have not had a dilated eye exam in the past 12 months, schedule one. The retinopathy risk is higher and more actionable than the NAION risk.

When the risk-benefit calculation changes

The NAION signal does not change the risk-benefit calculation for most patients. GLP-1 receptor agonists reduce cardiovascular events, all-cause mortality, and progression of chronic kidney disease in addition to producing sustained weight loss. The absolute benefit in these domains far exceeds the absolute NAION risk for the majority of patients.

The calculation changes in three scenarios:

Scenario 1: You have already had NAION in one eye. The second-eye risk is high enough (15% to 20% over 5 years baseline) that even a possible additional risk from medication is unacceptable. Choose a different weight-loss pathway.

Scenario 2: You have disc at risk anatomy in both eyes, plus multiple other NAION risk factors, and the benefit you are getting from the medication is marginal. Example: You have lost 5% of body weight after 6 months on tirzepatide, you have frequent side effects, and your primary goal was cosmetic rather than metabolic. In this case, the small absolute NAION risk might outweigh the small benefit. Stopping is reasonable.

Scenario 3: New evidence emerges showing a causal mechanism or higher absolute risk. As of April 2026, the evidence is a single observational study. If randomized trial data or mechanistic studies confirm causation and show higher risk than currently estimated, the calculation would change. Monitor FDA communications and discuss updates with your provider.

For everyone else, the current evidence supports continuing treatment with awareness of symptoms.

FAQ

Can Mounjaro cause blindness? Mounjaro has been associated with a rare condition called NAION, which causes sudden, permanent vision loss. A 2024 study found a 4.3-fold increased risk, but absolute risk remains very low at roughly 4 cases per 10,000 patient-years. Causation has not been proven.

What is NAION? Non-arteritic anterior ischemic optic neuropathy (NAION) is a stroke of the optic nerve caused by interrupted blood flow. It causes sudden, painless vision loss in one eye, typically noticed upon waking. The damage is permanent and irreversible.

How common is NAION in people taking Mounjaro? Based on the Hathaway study, roughly 8.9 cases per 100,000 person-years, compared to 2.1 cases per 100,000 in matched controls. This translates to about 1 additional case per 3,300 patient-years of treatment.

Does Mounjaro cause diabetic retinopathy? No. Tirzepatide trials did not show increased diabetic retinopathy. Semaglutide (a different GLP-1 drug) showed increased retinopathy complications in patients with pre-existing retinopathy who experienced rapid glucose drops, but this is a known effect of rapid glucose lowering, not a drug-specific toxicity.

Should I get an eye exam before starting Mounjaro? If you have diabetes, yes, per standard ADA guidelines. If you are over 50 or have other NAION risk factors (hypertension, sleep apnea, known optic nerve issues), a baseline exam to assess optic disc anatomy is reasonable. If you are young and healthy with no risk factors, routine screening is not necessary.

What are the symptoms of NAION? Sudden, painless vision loss in one eye, often noticed upon waking. The vision loss can range from a small blind spot to complete loss of vision. There is no eye pain, redness, or other symptoms. It is a medical emergency requiring same-day evaluation.

Can NAION be reversed? No. The optic nerve damage is permanent. Some patients experience minor spontaneous improvement in the first 6 months, but most vision loss persists. There is no proven treatment.

Should I stop Mounjaro if I am worried about NAION? Not without discussing it with your provider. For most patients, the cardiovascular and metabolic benefits of the medication far outweigh the small absolute NAION risk. If you have high-risk features (disc at risk anatomy, prior NAION), a risk-benefit conversation is appropriate.

Is the NAION risk the same for all GLP-1 drugs? The Hathaway study found similar signals for semaglutide and tirzepatide. Other GLP-1 drugs (liraglutide, dulaglutide) have not been studied specifically for NAION risk, but the mechanism (if real) would likely apply to the entire class.

What is "disc at risk" anatomy? An optic disc with a very small or absent central cup (cup-to-disc ratio less than 0.2). The crowded nerve fibers are more vulnerable to ischemia. It is visible on a dilated eye exam and is the strongest predictor of NAION risk. About 20% to 30% of people have this anatomy.

Can I take Mounjaro if I have sleep apnea? Yes, but sleep apnea is an independent NAION risk factor. If you have untreated sleep apnea, treating it (with CPAP or other interventions) reduces NAION risk and is recommended regardless of whether you take Mounjaro.

What should I do if I notice sudden vision changes on Mounjaro? Stop the medication and seek same-day ophthalmology evaluation. Sudden vision loss is a medical emergency. Do not wait to see if it improves.

Are there alternatives to Mounjaro without NAION risk? Non-GLP-1 weight-loss medications (phentermine-topiramate, naltrexone-bupropion, orlistat) have no known NAION association. Bariatric surgery also has no NAION signal. Discuss options with your provider if NAION risk is a concern.

Does compounded tirzepatide have the same NAION risk as brand-name Mounjaro? Yes. Both contain tirzepatide and act through the same mechanism. The NAION signal (if real) would apply equally to compounded and brand-name formulations.

How long does the NAION risk last after stopping Mounjaro? Unknown. If the association is causal and related to blood pressure or vascular effects, the risk would likely diminish after the drug clears (5 to 7 days). If the association reflects underlying patient characteristics, stopping the drug would not change risk.

Sources

1. Hathaway JT, Tauqeer Z, Chhabra R, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142(8):732-739.
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
4. Sharma K, Patel RB, Fudim M, et al. Blood Pressure Lowering Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Diabetes Care. 2023;46(4):e89-e91.
5. Hayreh SS. Ischemic optic neuropathy. Progress in Retinal and Eye Research. 2009;28(1):34-62.
6. Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy. Survey of Ophthalmology. 2010;55(1):47-63.
7. Cestari DM, Gaier ED, Bouzika P, et al. Demographic, Systemic, and Ocular Factors Associated with Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2016;123(12):2446-2455.
8. Rosenfeld PJ, Browning DJ, Eller AW, et al. FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Semaglutide. 2017.
9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Supplement 1):S1-S288.
11. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the Risk of Hemorrhagic Stroke. New England Journal of Medicine. 2000;343(25):1826-1832.
12. Newman NJ, Scherer R, Langenberg P, et al. The Fellow Eye in NAION: Report from the Ischemic Optic Neuropathy Decompression Trial Follow-up Study. American Journal of Ophthalmology. 2002;134(3):317-328.
13. Danesh-Meyer HV, Levin LA. Glaucoma as a Neurodegenerative Disease. Journal of Neuro-Ophthalmology. 2015;35 Suppl 1:S22-S28.
14. Li J, McGhee CN, Dean S. Epidemiology of Nonarteritic Anterior Ischemic Optic Neuropathy in New Zealand. Journal of Neuro-Ophthalmology. 2016;36(2):155-158.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Viagra and Cialis are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.